Search

Displaying results 581 - 590 of 825 in total
  1. Drug

    Influenza A virus A/Hong Kong/2671/2019 IVR-208 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB15712
    ApprovedWithdrawn

    In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  2. Drug

    Influenza A virus A/Guangdong-Maonan/SWL1536/2019 CNIC-1909 (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15714
    ApprovedWithdrawn

    In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  3. Drug

    Influenza B virus B/Phuket/3073/2013 BVR-1B antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15788
    ApprovedInvestigationalWithdrawn

    In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  4. Drug

    Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB16588
    Approved

    In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  5. Drug

    Influenza A virus A/Wisconsin/588/2019 (H1N1) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB16706
    Approved

    In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  6. Drug

    Influenza A virus A/Tasmania/503/2020 IVR-221 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB16721
    ApprovedWithdrawn

    In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  7. Drug

    Influenza A virus A/Washington/19/2020 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16727
    ApprovedWithdrawn

    In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  8. Drug

    Quizartinib

    go.drugbank.com/drugs/DB12874
    ApprovedInvestigational

    [A260641] Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although with a 10-fold lower affinity compared to wild-type FLT3.

  9. Drug

    Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB10596
    ApprovedWithdrawn

    In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  10. Drug

    Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB10597
    ApprovedWithdrawn

    In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.